Skip to main
OMCL

Omnicell (OMCL) Stock Forecast & Price Target

Omnicell (OMCL) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 60%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Omnicell is expected to continue experiencing strong revenue and earnings growth due to the increasingly crucial role that its automation and business analytics software plays in the healthcare industry, as demonstrated by its recent top and bottom-line beat in 1Q26. The company's introduction of the powerful Titan XT platform, as well as its recent acquisition of Surgichem IT has allowed it to expand its addressable market for its cloud-based medication management platform, OmniSphere, to an estimated $2.5 billion. The company's focus on customer satisfaction and loyalty, as evidenced by its strong customer feedback and high conversion rates from competitors, is a key factor in driving its continued success.

Bears say

Omnicell is showing signs of strong revenue growth in FY26 due to the introduction of new products like Titan XT and XTExtend, but these upgrades and new products are expected to come at a premium cost, potentially impacting the company's margin. While the company's recent stock performance may suggest positive sentiment, there are concerns about the sustainability of this growth and if the company can continue to meet market expectations. Investors should closely monitor the company's upcoming earnings report and conference call for insights into its long-term growth strategy and any potential challenges in the healthcare market.

Omnicell (OMCL) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 60% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Omnicell and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Omnicell (OMCL) Forecast

Analysts have given Omnicell (OMCL) a Buy based on their latest research and market trends.

According to 5 analysts, Omnicell (OMCL) has a Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Omnicell (OMCL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.